NEWS
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova announced two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress. The presentations highlighted the efficacy, safety, and tolerability of MN-001 (Tipelukast) for non-alcoholic fatty liver disease (NAFLD) and its metabolite MN-002's effects on cholesterol efflux. The Phase 2 clinical trial for MN-001 has enrolled 33 patients, with 14 completing the study. Three serious adverse events were reported but deemed unrelated to the drug. MN-002 was shown to significantly enhance cholesterol efflux and protein expression in a dose-dependent manner, with notable increases in ABCA1 and ABCG1 mRNA levels.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7425Visitors
Follow